Search

Your search keyword '"Meijer Sybren L"' showing total 50 results
Start Over Author "Meijer Sybren L" Database OAIster
50 results on '"Meijer Sybren L"'

1. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study

Author

MS Medische Oncologie, Cancer, Stroes, Charlotte I, Meijer, Sybren L, Creemers, Geert-Jan, Hooijer, Gerrit K J, Mohammad, Nadia Haj, Los, Maartje, Slingerland, Marije, Hospers, Geke A P, Cats, Annemieke, Beerepoot, Laurens V, Bijlsma, Maarten F, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, Stroes, Charlotte I, Meijer, Sybren L, Creemers, Geert-Jan, Hooijer, Gerrit K J, Mohammad, Nadia Haj, Los, Maartje, Slingerland, Marije, Hospers, Geke A P, Cats, Annemieke, Beerepoot, Laurens V, Bijlsma, Maarten F, and van Laarhoven, Hanneke W M

Published
2024

2. Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia:a nationwide cohort with pathology reassessment

Author

van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, Koch, Arjun D., van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, and Koch, Arjun D.

Abstract

BACKGROUND: This study evaluated the proportion of patients with residual neoplasia after endoscopic resection (ER) for Barrett's neoplasia with confirmed tumor-positive vertical resection margin (R1v). METHODS: This retrospective cohort study included patients undergoing ER for Barrett's neoplasia with histologically documented R1v since 2008 in the Dutch Barrett Expert Centers. We defined R1v as cancer cells touching vertical resection margins and Rx as nonassessable margins. Reassessment of R1v specimens was performed by experienced pathologists until consensus was reached regarding vertical margins. RESULTS: 101/110 included patients had macroscopically complete resections (17 T1a, 84 T1b), and 99/101 (98%) ER specimens were histologically reassessed, with R1v confirmed in 74 patients (75%), Rx in 16%, and R0 in 9%. Presence/absence of residual neoplasia could be assessed in 66/74 patients during endoscopic reassessment (52) and/or in the surgical resection specimen (14), and 33/66 (50%) had residual neoplasia. Residual neoplasia detected during endoscopy was always endoscopically visible and biopsies from a normal-appearing ER scar did not detect additional neoplasia. Of 25 patients who underwent endoscopic follow-up (median 37 months [interquartile range 12-50]), 4 developed local recurrence (16.0%), all detected as visible abnormalities. CONCLUSIONS: After ER with R1v, 50% of patients had no residual neoplasia. Histological evaluation of ER margins appears challenging, as in this study 75% of documented R1v cases were confirmed during reassessment. Endoscopic reassessment 8-12 weeks after ER seems to accurately detect residual neoplasia and can help to determine the most appropriate strategy for patients with R1v.

Published
2024

3. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

Author

Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., van Berge Henegouwen, Mark I., Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., and van Berge Henegouwen, Mark I.

Abstract

BACKGROUND: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. METHODS: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. RESULTS: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). CONCLUSION: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.

Published
2024

4. Increased PXR and Suppressed T-Cell Signaling Are Associated With Malignant Degeneration of Barrett's Esophagus

Author

Hoefnagel, Sanne J.M., Li, Shulin, Timmer, Eva M., Meijer, Sybren L., Krishnadath, Kausilia K., Hoefnagel, Sanne J.M., Li, Shulin, Timmer, Eva M., Meijer, Sybren L., and Krishnadath, Kausilia K.

Abstract

Background and Aims: Barrett's esophagus (BE) is the precursor lesion for esophageal adenocarcinoma (EAC). To detect EAC in early stage, patients with BE undergo endoscopic surveillance. Surveillance cohorts largely consist of nondysplastic BE (NDBE) patients with a low annual progression risk (<0.5%). Predictive biomarkers for malignant progression of NDBE could improve efficacy of surveillance. Biomarker research has mostly focused on aberrant protein expression on BE epithelial cells. Moreover, insight in cell signaling driving malignant transformation is unknown. This study uses a data-driven approach to analyze tumor-stroma interaction in NDBE which progressed to high-grade dysplasia or EAC. Methods: In this case-control study, we performed RNA sequencing analysis on index NDBE biopsies from 6 patients who, during long-term follow-up, progressed and 7 who did not progress to high-grade dysplasia/EAC. For control samples, squamous and duodenum tissues from BE patients were analyzed. For validation, we used quantitative PCR. Results: Significant differences in BE transcriptomic profiles between progressors and nonprogressors were found by principal component and differential expression analyses. Ingenuity pathway analysis indicated that 8 cell signaling pathways were significantly upregulated in the progressors, and 14 pathways were significantly downregulated. The most interesting finding was the upregulation of the xenobiotic metabolism pregnane X receptor signaling pathway in the progressor cohort, while of the downregulated pathways in progressors, several were related to the immune system. Conclusion: These novel transcriptomic insights are fundamental for developing (chemo-)preventive therapies. These could be therapies, which protect against toxins, including biles, responsible for pregnane X receptor activation or which enhance protective immune mechanisms. The identified R

Published
2023

5. Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrett's esophagus: a multicenter randomized study

Author

van Munster, Sanne N, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J, Kariv, Revital, Neuhaus, Horst, Weusten, Bas L A M, Siersema, Peter D, Correale, Loredana, Meijer, Sybren L, de Hertogh, Gert, Bergman, Jacques J G H M, Hassan, Cesare, Bisschops, Raf, van Munster, Sanne N, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J, Kariv, Revital, Neuhaus, Horst, Weusten, Bas L A M, Siersema, Peter D, Correale, Loredana, Meijer, Sybren L, de Hertogh, Gert, Bergman, Jacques J G H M, Hassan, Cesare, and Bisschops, Raf

Abstract

BACKGROUND: Current surveillance for Barrett's esophagus (BE), consisting of four-quadrant random forceps biopsies (FBs), has an inherent risk of sampling error. Wide-area transepithelial sampling (WATS) may increase detection of high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). In this multicenter randomized trial, we aimed to evaluate WATS as a substitute for FB.METHODS: Patients with known BE and a recent history of dysplasia, without visible lesions, at 17 hospitals were randomized to receive either WATS followed by FB or vice versa. All WATS samples were examined, with computer assistance, by at least two experienced pathologists at the CDx Diagnostics laboratory. Similarly, all FBs were examined by two expert pathologists. The primary end point was concordance/discordance for detection of HGD/EAC between the two techniques.RESULTS: 172 patients were included, of whom 21 had HGD/EAC detected by both modalities, 18 had HGD/EAC detected by WATS but missed by FB, and 12 were detected by FB but missed by WATS. The detection rate of HGD/EAC did not differ between WATS and FB (P = 0.36). Using WATS as an adjunct to FB significantly increased the detection of HGD/EAC vs. FB alone (absolute increase 10 % [95 %CI 6 % to 16 %]). Mean procedural times in minutes for FB alone, WATS alone, and the combination were 6.6 (95 %CI 5.9 to 7.1), 4.9 (95 %CI 4.1 to 5.4), and 11.2 (95 %CI 10.5 to 14.0), respectively.CONCLUSIONS: Although the combination of WATS and FB increases dysplasia detection in a population of BE patients enriched for dysplasia, we did not find a statistically significant difference between WATS and FB for the detection of HGD/EAC as single modality.

Published
2023

6. Feasibility and Safety of Tailored Lymphadenectomy Using Sentinel Node-Navigated Surgery in Patients with High-Risk T1 Esophageal Adenocarcinoma

Author

Unit Opleiding Aios, Cancer, MS MDL 1, MS Radiologie, Pathologie Pathologen staf, MS CGO, Frederiks, Charlotte N, Overwater, Anouk, Bergman, Jacques J G H M, Pouw, Roos E, de Keizer, Bart, Bennink, Roel J, Brosens, Lodewijk A A, Meijer, Sybren L, van Hillegersberg, Richard, van Berge Henegouwen, Mark I, Ruurda, Jelle P, Gisbertz, Suzanne S, Weusten, Bas L A M, Unit Opleiding Aios, Cancer, MS MDL 1, MS Radiologie, Pathologie Pathologen staf, MS CGO, Frederiks, Charlotte N, Overwater, Anouk, Bergman, Jacques J G H M, Pouw, Roos E, de Keizer, Bart, Bennink, Roel J, Brosens, Lodewijk A A, Meijer, Sybren L, van Hillegersberg, Richard, van Berge Henegouwen, Mark I, Ruurda, Jelle P, Gisbertz, Suzanne S, and Weusten, Bas L A M

Published
2023

7. Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures

Author

van Munster, Sanne N, van Munster, Sanne N, Verheij, Eva P D, Nieuwenhuis, Esther A, Offerhaus, Johan G J A, Meijer, Sybren L, Brosens, Lodewijk A A, Weusten, Bas L A M, Alkhalaf, Alaa, Schenk, Ed B E, Schoon, Erik J, Curvers, Wouter L, van Tilburg, Laurelle, van de Ven, Steffi E M, Tang, Thjon J, Nagengast, Wouter B, Houben, Martin H M G, Seldenrijk, Kees C A, Bergman, Jacques J G H M, Koch, Arjun D, Pouw, Roos E, Dutch Barrett Expert Centers, van Munster, Sanne N, van Munster, Sanne N, Verheij, Eva P D, Nieuwenhuis, Esther A, Offerhaus, Johan G J A, Meijer, Sybren L, Brosens, Lodewijk A A, Weusten, Bas L A M, Alkhalaf, Alaa, Schenk, Ed B E, Schoon, Erik J, Curvers, Wouter L, van Tilburg, Laurelle, van de Ven, Steffi E M, Tang, Thjon J, Nagengast, Wouter B, Houben, Martin H M G, Seldenrijk, Kees C A, Bergman, Jacques J G H M, Koch, Arjun D, Pouw, Roos E, and Dutch Barrett Expert Centers

Abstract

BACKGROUND: The use of endoscopic submucosal dissection (ESD) is gradually expanding for treatment of neoplasia in Barrett's esophagus (BE). We aimed to report outcomes of all ESDs for BE neoplasia performed in the Netherlands.METHODS: Retrospective assessment of outcomes, using treatment and follow-up data from a joint database.RESULTS: 130/138 patients had complete ESDs, with 126/130 (97 %) en bloc resections. Median (interquartile range (IQR)) procedure time was 121 minutes (90-180). Pathology findings were high grade dysplasia (HGD) (5 %) or esophageal adenocarcinoma (EAC) T1a (43 %) or T1b (52 %; 19 % sm1, 33 % ≥ sm2). Among resections of HGD or T1a EAC lesions, 87 % (95 %CI 75 %-92 %) were both en bloc and R0; the corresponding value for T1b EAC lesions was 49 % (36 %-60 %). Among R1 resections, 10/34 (29 %) showed residual cancer, all detected at first endoscopic follow-up. The remaining 24 patients (71 %) showed no residual neoplasia. Six of these patients underwent surgery with no residual tumor; the remaining 18 underwent endoscopic follow-up during median 31 months with 1 local recurrence (annual recurrence rate 2 %). Among R0 resections, annual local recurrence rate during median 27 months was 0.5 %.CONCLUSION: In expert hands, ESD allows safe removal of bulky intraluminal neoplasia and submucosal cancer. ESD of the latter showed R1 resection margins in 50 %, yet only one third had persisting neoplasia at follow-up. To better stratify R1 patients with an indication for additional surgery, repeat endoscopy after healing of the ESD might be a helpful possible prognostic factor for residual cancer.

Published
2022

8. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma

Author

Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, L., Jansen, Marnix, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Tang, Thjon, Bergman, Jacques J.G.H.M., Pouw, Roos E., Meijer, S., Doukas, M., Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, L., Jansen, Marnix, Weusten, Bas L.A.M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M.G., Tang, Thjon, Bergman, Jacques J.G.H.M., Pouw, Roos E., Meijer, S., and Doukas, M.

Abstract

Background and Aims: After endoscopic resection (ER) of early esophageal adenocarcinoma (EAC), the optimal management of patients with high-risk histologic features for lymph node metastases (ie, submucosal invasion, poor differentiation grade, or lymphovascular invasion) remains unclear. We aimed to evaluate outcomes of endoscopic follow-up after ER for high-risk EAC. Methods: For this retrospective cohort study, data were collected from all Dutch patients managed with endoscopic follow-up (endoscopy, EUS) after ER for high-risk EAC between 2008 and 2019. We distinguished 3 groups: intramucosal cancers with high-risk features, submucosal cancers with low-risk features, and submucosal cancers with high-risk features. The primary outcome was the annual risk for metastases during follow-up, stratified for baseline histology. Results: One hundred twenty patients met the selection criteria. Median follow-up was 29 months (interquartile range, 15-48). Metastases were observed in 5 of 25 (annual risk, 6.9%; 95% confidence interval [CI], 3.0-15) high-risk intramucosal cancers, 1 of 55 (annual risk, .7%; 95% CI, 0-4.0) low-risk submucosal cancers, and 3 of 40 (annual risk, 3.0%; 95% CI, 0-7.0) high-risk submucosal cancers. Conclusions: Whereas the annual metastasis rate for high-risk submucosal EAC (3.0%) was somewhat lower than expected in comparison with previous reported percentages, the annual metastasis rate of 6.9% for high-risk intramucosal EAC is new and worrisome. This calls for further prospective studies and suggests that strict follow-up of this small subgroup is warranted until prospective data are available.

Published
2022

9. Extending treatment criteria for Barrett's neoplasia:Results of a nationwide cohort of 138 endoscopic submucosal dissection procedures

Author

Van Munster, Sanne N., Verheij, Eva P.D., Nieuwenhuis, Esther A., Offerhaus, Johan G.J.A., Meijer, Sybren L., Brosens, Lodewijk A.A., Weusten, Bas L.A.M., Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter L., Van Tilburg, Laurelle, Van De Ven, Steffi E.M., Tang, Thjon J., Nagengast, Wouter B., Houben, Martin H.M.G., Seldenrijk, Kees C.A., Bergman, Jacques J.G.H.M., Koch, Arjun D., Pouw, Roos E., Van Munster, Sanne N., Verheij, Eva P.D., Nieuwenhuis, Esther A., Offerhaus, Johan G.J.A., Meijer, Sybren L., Brosens, Lodewijk A.A., Weusten, Bas L.A.M., Alkhalaf, Alaa, Schenk, Ed B.E., Schoon, Erik J., Curvers, Wouter L., Van Tilburg, Laurelle, Van De Ven, Steffi E.M., Tang, Thjon J., Nagengast, Wouter B., Houben, Martin H.M.G., Seldenrijk, Kees C.A., Bergman, Jacques J.G.H.M., Koch, Arjun D., and Pouw, Roos E.

Abstract

Background The use of endoscopic submucosal dissection (ESD) is gradually expanding for treatment of neoplasia in Barrett s esophagus (BE). We aimed to report outcomes of all ESDs for BE neoplasia performed in the Netherlands. Methods Retrospective assessment of outcomes, using treatment and follow-up data from a joint database. Results 130/138 patients had complete ESDs, with 126/ 130 (97%) en bloc resections. Median (interquartile range (IQR)) procedure time was 121 minutes (90 180). Pathology findings were high grade dysplasia (HGD) (5 %) or esophageal adenocarcinoma (EAC) T1a (43 %) or T1b (52%; 19% sm1, 33%≤sm2). Among resections of HGD or T1a EAC lesions, 87% (95%CI 75% 92 %) were both en bloc and R0; the corresponding value for T1b EAC lesions was 49% (36% 60 %). Among R1 resections, 10/34 (29%) showed residual cancer, all detected at first endoscopic follow-up. The remaining 24 patients (71 %) showed no residual neoplasia. Six of these patients underwent surgery with no residual tumor; the remaining 18 underwent endoscopic follow-up during median 31 months with 1 local recurrence (annual recurrence rate 2 %). Among R0 resections, annual local recurrence rate during median 27 months was 0.5 %. Conclusion In expert hands, ESD allows safe removal of bulky intraluminal neoplasia and submucosal cancer. ESD of the latter showed R1 resection margins in 50%, yet only one third had persisting neoplasia at follow-up. To better stratify R1 patients with an indication for additional surgery, repeat endoscopy after healing of the ESD might be a helpful possible prognostic factor for residual cancer.

Published
2022

10. Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies

Author

Hoefnagel, Sanne J. M., Koemans, Willem J., Khan, Hina N., Koster, Jan, Meijer, Sybren L., van Dieren, Jolanda M., Kodach, Liudmila L., van Sandick, Johanna W., Calpe, Silvia, del Sancho-Serra, Carmen M., Correia, Ana C. P., Henegouwen, Mark I. Van Berge, Gisbertz, Suzanne S., Hulshof, Maarten C. C. M., Mattioli, Sandro, Spaander, Manon C. W., Krishnadath, Kausilia K., Hoefnagel, Sanne J. M., Koemans, Willem J., Khan, Hina N., Koster, Jan, Meijer, Sybren L., van Dieren, Jolanda M., Kodach, Liudmila L., van Sandick, Johanna W., Calpe, Silvia, del Sancho-Serra, Carmen M., Correia, Ana C. P., Henegouwen, Mark I. Van Berge, Gisbertz, Suzanne S., Hulshof, Maarten C. C. M., Mattioli, Sandro, Spaander, Manon C. W., and Krishnadath, Kausilia K.

Abstract

Esophageal adenocarcinoma (EAC) is a highly aggressive cancer and its response to chemo- and radiotherapy is unpredictable. EACs are highly heterogeneous at the molecular level. The aim of this study was to perform gene expression analysis of EACs to identify distinct molecular subgroups and to investigate expression signatures in relation to treatment response. In this prospective observational study, RNA sequencing was performed on pre-treatment endoscopic EAC biopsies from a discovery cohort included between 2012 and 2017 in one Dutch Academic Center. Four additional cohorts were analyzed for validation purposes. Unsupervised clustering was performed on 107 patients to identify biological EAC subgroups. Specific cell signaling profiles were identified and evaluated with respect to predicting response to neo-adjuvant chemo(radio)therapy. We identified and validated three distinct biological EAC subgroups, characterized by (1) p38 MAPK/Toll-like receptor signaling; (2) activated immune system; and (3) impaired cell adhesion. Subgroup 1 was associated with poor response to chemo-radiotherapy. Moreover, an immune signature with activated T-cell signaling, and increased number of activated CD4 T memory cells, neutrophils and dendritic cells, and decreased M1 and M2 macrophages and plasma cells, was associated with complete histopathological response. This study provides a novel molecular classification for EACs. EAC subgroup 1 proved to be more therapy-resistant, while immune signaling was increased in patients with complete response to chemo-radiotherapy. Our findings give insight into the biology of EACs and in cellular signaling mechanisms underlying response to neo-adjuvant treatment. Future implementation of this classification will improve patient stratification and enhance the development of targeted therapies.

Published
2022

11. Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures

Author

van Munster, Sanne N, Verheij, Eva P D, Nieuwenhuis, Esther A, Offerhaus, Johan G J A, Meijer, Sybren L, Brosens, Lodewijk A A, Weusten, Bas L A M, Alkhalaf, Alaa, Schenk, Ed B E, Schoon, Erik J, Curvers, Wouter L, van Tilburg, Laurelle, van de Ven, Steffi E M, Tang, Thjon J, Nagengast, Wouter B, Houben, Martin H M G, Seldenrijk, Kees C A, Bergman, Jacques J G H M, Koch, Arjun D, Pouw, Roos E, Dutch Barrett Expert Centers, van Munster, Sanne N, Verheij, Eva P D, Nieuwenhuis, Esther A, Offerhaus, Johan G J A, Meijer, Sybren L, Brosens, Lodewijk A A, Weusten, Bas L A M, Alkhalaf, Alaa, Schenk, Ed B E, Schoon, Erik J, Curvers, Wouter L, van Tilburg, Laurelle, van de Ven, Steffi E M, Tang, Thjon J, Nagengast, Wouter B, Houben, Martin H M G, Seldenrijk, Kees C A, Bergman, Jacques J G H M, Koch, Arjun D, Pouw, Roos E, and Dutch Barrett Expert Centers

Abstract

BACKGROUND: The use of endoscopic submucosal dissection (ESD) is gradually expanding for treatment of neoplasia in Barrett's esophagus (BE). We aimed to report outcomes of all ESDs for BE neoplasia performed in the Netherlands.METHODS: Retrospective assessment of outcomes, using treatment and follow-up data from a joint database.RESULTS: 130/138 patients had complete ESDs, with 126/130 (97 %) en bloc resections. Median (interquartile range (IQR)) procedure time was 121 minutes (90-180). Pathology findings were high grade dysplasia (HGD) (5 %) or esophageal adenocarcinoma (EAC) T1a (43 %) or T1b (52 %; 19 % sm1, 33 % ≥ sm2). Among resections of HGD or T1a EAC lesions, 87 % (95 %CI 75 %-92 %) were both en bloc and R0; the corresponding value for T1b EAC lesions was 49 % (36 %-60 %). Among R1 resections, 10/34 (29 %) showed residual cancer, all detected at first endoscopic follow-up. The remaining 24 patients (71 %) showed no residual neoplasia. Six of these patients underwent surgery with no residual tumor; the remaining 18 underwent endoscopic follow-up during median 31 months with 1 local recurrence (annual recurrence rate 2 %). Among R0 resections, annual local recurrence rate during median 27 months was 0.5 %.CONCLUSION: In expert hands, ESD allows safe removal of bulky intraluminal neoplasia and submucosal cancer. ESD of the latter showed R1 resection margins in 50 %, yet only one third had persisting neoplasia at follow-up. To better stratify R1 patients with an indication for additional surgery, repeat endoscopy after healing of the ESD might be a helpful possible prognostic factor for residual cancer.

Published
2022

12. Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrettʼs esophagus: A Multi-Center, Randomized Study

Author

MS MDL 1, Cancer, Van Munster, Sanne, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J., Kariv, Revital, Neuhaus, Horst, Weusten, Bas L.A.M., Siersema, Peter D., Correale, Loredana, Meijer, Sybren L., De Hertogh, Gert, Bergman, Jacques Jghm, Hassan, Cesare, Bisschops, Raf, MS MDL 1, Cancer, Van Munster, Sanne, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J., Kariv, Revital, Neuhaus, Horst, Weusten, Bas L.A.M., Siersema, Peter D., Correale, Loredana, Meijer, Sybren L., De Hertogh, Gert, Bergman, Jacques Jghm, Hassan, Cesare, and Bisschops, Raf

Published
2022

13. Feasibility of sentinel node navigated surgery in high-risk T1b esophageal adenocarcinoma patients using a hybrid tracer of technetium-99 m and indocyanine green

Author

MS MDL 1, Cancer, MS CGO, MS Radiologie, Pathologie Pathologen staf, Overwater, Anouk, Weusten, Bas L A M, Ruurda, Jelle P, van Hillegersberg, Richard, Bennink, Roel J, de Keizer, Bart, Meijer, Sybren L, Brosens, Lodewijk A A, Pouw, Roos E, Bergman, Jacques J G H M, van Berge Henegouwen, Mark I, Gisbertz, Suzanne S, MS MDL 1, Cancer, MS CGO, MS Radiologie, Pathologie Pathologen staf, Overwater, Anouk, Weusten, Bas L A M, Ruurda, Jelle P, van Hillegersberg, Richard, Bennink, Roel J, de Keizer, Bart, Meijer, Sybren L, Brosens, Lodewijk A A, Pouw, Roos E, Bergman, Jacques J G H M, van Berge Henegouwen, Mark I, and Gisbertz, Suzanne S

Published
2022

14. Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study

Author

Pathologie, MS MDL 1, Cancer, Pathologie Pathologen staf, MS CGO, Trialbureau Beeld, Gotink, Annieke W, van de Ven, Steffi Elisabeth Maria, Ten Kate, Fiebo Jw, Nieboer, Daan, Suzuki, Lucia, Weusten, Bas L A M, Brosens, Lodewijk A A, van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, C A, Alkhalaf, Alaa, Moll, F C P, Schoon, Erik J, van Lijnschoten, Ineke, Tang, Thjon J, van der Valk, Hans, Nagengast, Wouter B, Kats-Ugurlu, Gursah, Plukker, John T M, Houben, Martin H M G, van der Laan, J S, Pouw, Roos E, Bergman, Jacques J G H M, Meijer, Sybren L, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, de Jonge, Pieter J F, Doukas, Michael, Bruno, Marco J, Biermann, Katharina, Koch, Arjun Dave, Pathologie, MS MDL 1, Cancer, Pathologie Pathologen staf, MS CGO, Trialbureau Beeld, Gotink, Annieke W, van de Ven, Steffi Elisabeth Maria, Ten Kate, Fiebo Jw, Nieboer, Daan, Suzuki, Lucia, Weusten, Bas L A M, Brosens, Lodewijk A A, van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, C A, Alkhalaf, Alaa, Moll, F C P, Schoon, Erik J, van Lijnschoten, Ineke, Tang, Thjon J, van der Valk, Hans, Nagengast, Wouter B, Kats-Ugurlu, Gursah, Plukker, John T M, Houben, Martin H M G, van der Laan, J S, Pouw, Roos E, Bergman, Jacques J G H M, Meijer, Sybren L, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, de Jonge, Pieter J F, Doukas, Michael, Bruno, Marco J, Biermann, Katharina, and Koch, Arjun Dave

Published
2022

15. Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma:A multicenter cohort study

Author

Gotink, Annieke W., Van De Ven, Steffi E.M., Ten Kate, Fiebo J.C., Nieboer, Daan, Suzuki, Lucia, Weusten, Bas L.A.M., Brosens, Lodewijk A.A., Van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A., Alkhalaf, Alaa, Moll, Freek C.P., Schoon, Erik J., Van Lijnschoten, Ineke, Tang, Thjon J., Van Der Valk, Hans, Nagengast, Wouter B., Kats-Ugurlu, Gursah, Plukker, John T.M., Houben, Martin H.M.G., Van Der Laan, Jaap S., Pouw, Roos E., Bergman, Jacques J.G.H.M., Meijer, Sybren L., Van Berge Henegouwen, Mark I., Wijnhoven, Bas P.L., De Jonge, Pieter Jan F., Doukas, Michael, Bruno, Marco J., Biermann, Katharina, Koch, Arjun D., Gotink, Annieke W., Van De Ven, Steffi E.M., Ten Kate, Fiebo J.C., Nieboer, Daan, Suzuki, Lucia, Weusten, Bas L.A.M., Brosens, Lodewijk A.A., Van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A., Alkhalaf, Alaa, Moll, Freek C.P., Schoon, Erik J., Van Lijnschoten, Ineke, Tang, Thjon J., Van Der Valk, Hans, Nagengast, Wouter B., Kats-Ugurlu, Gursah, Plukker, John T.M., Houben, Martin H.M.G., Van Der Laan, Jaap S., Pouw, Roos E., Bergman, Jacques J.G.H.M., Meijer, Sybren L., Van Berge Henegouwen, Mark I., Wijnhoven, Bas P.L., De Jonge, Pieter Jan F., Doukas, Michael, Bruno, Marco J., Biermann, Katharina, and Koch, Arjun D.

Abstract

Background Lymph node metastasis (LNM) is possible after endoscopic resection of early esophageal adenocarcinoma (EAC). This study aimed to develop and internally validate a prediction model that estimates the individual risk of metastases in patients with pT1b EAC.Methods A nationwide, retrospective, multicenter cohort study was conducted in patients with pT1b EAC treated with endoscopic resection and/or surgery between 1989 and 2016. The primary end point was presence of LNM in surgical resection specimens or detection of metastases during follow-up.All resection specimens were histologically reassessed by specialist gastrointestinal pathologists. Subdistribution hazard regression analysis was used to develop the prediction model. The discriminative ability of this model was assessed using the c-statistic.Results 248 patients with pT1b EAC were included. Metastases were seen in 78 patients, and the 5-year cumulative incidence was 30.9% (95% confidence interval [CI] 25.1%-36.8%). The risk of metastases increased with submucosal invasion depth (subdistribution hazard ratio [SHR] 1.08, 95%CI 1.02-1.14, for every increase of 500 mu m), lymphovascular invasion (SHR 2.95, 95%CI 1.95-4.45), and for larger tumors (SHR 1.23, 95%CI 1.10-1.37, for every increase of 10mm). The model demonstrated good discriminative ability (c-statistic 0.81, 95%CI 0.75-0.86).Conclusions A third of patients with pT1b EAC experienced metastases within 5 years. The probability of developing post-resection metastases was estimated with a personalized predicted risk score incorporating tumor invasion depth, tumor size, and lymphovascular invasion. This model requires external validation before implementation into clinical practice.

Published
2021

16. Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma

Author

van de Ven, Steffi E.M., Suzuki, Lucia, Gotink, Annieke W., ten Kate, Fiebo J.C., Nieboer, Daan, Weusten, Bas L.A.M., Brosens, Lodewijk A.A., van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A., Alkhalaf, Alaa, Moll, Freek C.P., Curvers, Wouter, van Lijnschoten, Ineke G., Tang, Thjon J., van der Valk, Hans, Nagengast, Wouter B., Kats-Ugurlu, Gursah, Plukker, John T.M., Houben, Martin H.M.G., van der Laan, Jaap S., Pouw, Roos E., Bergman, Jacques J.G.H.M., Meijer, Sybren L., van Berge Henegouwen, Mark I., Wijnhoven, Bas P.L., de Jonge, Pieter J.F., Doukas, Michael, Bruno, Marco J., Biermann, Katharina, Koch, Arjun D., van de Ven, Steffi E.M., Suzuki, Lucia, Gotink, Annieke W., ten Kate, Fiebo J.C., Nieboer, Daan, Weusten, Bas L.A.M., Brosens, Lodewijk A.A., van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A., Alkhalaf, Alaa, Moll, Freek C.P., Curvers, Wouter, van Lijnschoten, Ineke G., Tang, Thjon J., van der Valk, Hans, Nagengast, Wouter B., Kats-Ugurlu, Gursah, Plukker, John T.M., Houben, Martin H.M.G., van der Laan, Jaap S., Pouw, Roos E., Bergman, Jacques J.G.H.M., Meijer, Sybren L., van Berge Henegouwen, Mark I., Wijnhoven, Bas P.L., de Jonge, Pieter J.F., Doukas, Michael, Bruno, Marco J., Biermann, Katharina, and Koch, Arjun D.

Abstract

Aim: To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma. Methods: In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow-up. A prediction model to identify risk factors for metastases was developed and internally validated. Results: 248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy-eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c-statistic 0.81). Conclusion: The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.

Published
2021

17. Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma

Author

MS MDL 1, Cancer, Pathologie Pathologen staf, MS CGO, van de Ven, Steffi E M, Suzuki, Lucia, Gotink, Annieke W, Ten Kate, Fiebo J C, Nieboer, Daan, Weusten, Bas L A M, Brosens, Lodewijk A A, van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A, Alkhalaf, Alaa, Moll, Freek C P, Curvers, Wouter, van Lijnschoten, Ineke G, Tang, Thjon J, van der Valk, Hans, Nagengast, Wouter B, Kats-Ugurlu, Gursah, Plukker, John T M, Houben, Martin H M G, van der Laan, Jaap S, Pouw, Roos E, Bergman, Jacques J G H M, Meijer, Sybren L, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, de Jonge, Pieter J F, Doukas, Michael, Bruno, Marco J, Biermann, Katharina, Koch, Arjun D, MS MDL 1, Cancer, Pathologie Pathologen staf, MS CGO, van de Ven, Steffi E M, Suzuki, Lucia, Gotink, Annieke W, Ten Kate, Fiebo J C, Nieboer, Daan, Weusten, Bas L A M, Brosens, Lodewijk A A, van Hillegersberg, Richard, Alvarez Herrero, Lorenza, Seldenrijk, Cees A, Alkhalaf, Alaa, Moll, Freek C P, Curvers, Wouter, van Lijnschoten, Ineke G, Tang, Thjon J, van der Valk, Hans, Nagengast, Wouter B, Kats-Ugurlu, Gursah, Plukker, John T M, Houben, Martin H M G, van der Laan, Jaap S, Pouw, Roos E, Bergman, Jacques J G H M, Meijer, Sybren L, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, de Jonge, Pieter J F, Doukas, Michael, Bruno, Marco J, Biermann, Katharina, and Koch, Arjun D

Published
2021

18. ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES

Author

Pathologie Pathologen staf, Cancer, MS MDL 1, Verheij, Eva P., Van Munster, Sanne N., Nieuwenhuis, Esther, van Tilburg, Laurelle, Offerhaus, Johan, Meijer, Sybren L., Brosens, Lodewijk A., Weusten, Bas L., Alkhalaf, A., Schenk, B. E., Schoon, Erik. J., Curvers, Wouter, Van De Ven, Steffi E., Nagengast, Wouter B., Houben, Martin H., Bergman, Jacques, Koch, Arjun D., Pouw, Roos E., Pathologie Pathologen staf, Cancer, MS MDL 1, Verheij, Eva P., Van Munster, Sanne N., Nieuwenhuis, Esther, van Tilburg, Laurelle, Offerhaus, Johan, Meijer, Sybren L., Brosens, Lodewijk A., Weusten, Bas L., Alkhalaf, A., Schenk, B. E., Schoon, Erik. J., Curvers, Wouter, Van De Ven, Steffi E., Nagengast, Wouter B., Houben, Martin H., Bergman, Jacques, Koch, Arjun D., and Pouw, Roos E.

Published
2021

19. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

Author

MS Medische Oncologie, Cancer, MS CGO, Stroes, Charlotte I, Schokker, Sandor, Molenaar, Remco J, Mathôt, Ron A A, Bijlsma, Maarten F, van der Woude, Stephanie O, Belo Pereira, João P, Hooijer, Gerrit K J, Verhoeven, Rob H A, Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W, Creemers, Geert-Jan, Nieuwenhuijzen, Grard A P, Haj Mohammad, Nadia, Ruurda, Jelle P, Meijer, Sybren L, Hulshof, Maarten C C M, van Berge Henegouwen, Mark I, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, MS CGO, Stroes, Charlotte I, Schokker, Sandor, Molenaar, Remco J, Mathôt, Ron A A, Bijlsma, Maarten F, van der Woude, Stephanie O, Belo Pereira, João P, Hooijer, Gerrit K J, Verhoeven, Rob H A, Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W, Creemers, Geert-Jan, Nieuwenhuijzen, Grard A P, Haj Mohammad, Nadia, Ruurda, Jelle P, Meijer, Sybren L, Hulshof, Maarten C C M, van Berge Henegouwen, Mark I, and van Laarhoven, Hanneke W M

Published
2021

20. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)

Author

MS Medische Oncologie, Cancer, MS CGO, van den Ende, Tom, Clercq, Nicolien de, van Berge Henegouwen, Mark I, UMC, Amsterdam, Geijsen, Debby, Verhoeven, Rob, Meijer, Sybren L, Schokker, Sandor, Dings, Mark, Bergman, Jacques J G H M, Haj Mohammad, Nadia, Ruurda, Jelle P, van Hillegersberg, Richard, Mook, Stella, Nieuwdorp, Max, de Gruijl, Tanja D, Soeratram, Tanya T D, Ylstra, Bauke, van Grieken, Nicole C T, Bijlsma, Maarten F, Hulshof, Maarten C C M, van Laarhoven, Hanneke W, MS Medische Oncologie, Cancer, MS CGO, van den Ende, Tom, Clercq, Nicolien de, van Berge Henegouwen, Mark I, UMC, Amsterdam, Geijsen, Debby, Verhoeven, Rob, Meijer, Sybren L, Schokker, Sandor, Dings, Mark, Bergman, Jacques J G H M, Haj Mohammad, Nadia, Ruurda, Jelle P, van Hillegersberg, Richard, Mook, Stella, Nieuwdorp, Max, de Gruijl, Tanja D, Soeratram, Tanya T D, Ylstra, Bauke, van Grieken, Nicole C T, Bijlsma, Maarten F, Hulshof, Maarten C C M, and van Laarhoven, Hanneke W

Published
2021

21. FEASIBILITY OF SENTINEL NODE NAVIGATION SURGERY IN PATIENTS WITH HIGH-RISK SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA USING A HYBRID TRACER OF TECHNETIUM-99M AND INDOCYANINE GREEN

Author

MS MDL 1, Cancer, MS CGO, MS Radiologie, Pathologie Pathologen staf, Overwater, Anouk, Weusten, Bas L., Ruurda, Jelle, van Hillegersberg, R., Bennink, Roel J., de Keizer, Bart, Meijer, Sybren L., Brosens, Lodewijk A., Pouw, Roos E., Bergman, Jacques, Henegouwen, Mark I. van Berge, Gisbertz, Suzanne, MS MDL 1, Cancer, MS CGO, MS Radiologie, Pathologie Pathologen staf, Overwater, Anouk, Weusten, Bas L., Ruurda, Jelle, van Hillegersberg, R., Bennink, Roel J., de Keizer, Bart, Meijer, Sybren L., Brosens, Lodewijk A., Pouw, Roos E., Bergman, Jacques, Henegouwen, Mark I. van Berge, and Gisbertz, Suzanne

Published
2020

22. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study

Author

MS Medische Oncologie, Cancer, Dijksterhuis, Willemieke P M, Verhoeven, Rob H A, Meijer, Sybren L, Slingerland, Marije, Haj Mohammad, Nadia, de Vos-Geelen, Judith, Beerepoot, Laurens V, van Voorthuizen, Theo, Creemers, Geert-Jan, van Oijen, Martijn G H, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, Dijksterhuis, Willemieke P M, Verhoeven, Rob H A, Meijer, Sybren L, Slingerland, Marije, Haj Mohammad, Nadia, de Vos-Geelen, Judith, Beerepoot, Laurens V, van Voorthuizen, Theo, Creemers, Geert-Jan, van Oijen, Martijn G H, and van Laarhoven, Hanneke W M

Published
2020

23. Distribution of lymph node metastases in esophageal carcinoma [TIGER study] : Study protocol of a multinational observational study

Author

Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., Gisbertz, Suzanne S., Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., and Gisbertz, Suzanne S.

Published
2019

24. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study

Author

Hagens, Eliza R. C., Henegouwen, Mark I. van Berge, van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Rasanen, Jari, Nafteux, Philippe, Pattyn, Piet, Hoelscher, Arnulf H., Schroeder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Roig Garcia, Josep, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flavio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., Gisbertz, Suzanne S., Hagens, Eliza R. C., Henegouwen, Mark I. van Berge, van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Rasanen, Jari, Nafteux, Philippe, Pattyn, Piet, Hoelscher, Arnulf H., Schroeder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Roig Garcia, Josep, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flavio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., and Gisbertz, Suzanne S.

Abstract

BackgroundAn important parameter for survival in patients with esophageal carcinoma is lymph node status. The distribution of lymph node metastases depends on tumor characteristics such as tumor location, histology, invasion depth, and on neoadjuvant treatment. The exact distribution is unknown. Neoadjuvant treatment and surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy has not been reached. The aim of this study is to determine the distribution of lymph node metastases in patients with resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed. This can be the foundation for a uniform worldwide staging system and establishment of the optimal surgical strategy for esophageal cancer patients.MethodsThe TIGER study is an international observational cohort study with 50 participating centers. Patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately individually analyzed by pathological examination. The aim is to include 5000 patients. The primary endpoint is the distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival.DiscussionThe TIGER study will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatmen

Published
2019

25. Distribution of lymph node metastases in esophageal carcinoma [TIGER study] : Study protocol of a multinational observational study

Author

Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., Gisbertz, Suzanne S., Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., and Gisbertz, Suzanne S.

Published
2019

26. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: Study protocol of a multinational observational study

Author

Divisie Beeld & Oncologie, Cancer, Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., Gisbertz, Suzanne S., Divisie Beeld & Oncologie, Cancer, Hagens, Eliza R.C., Van Berge Henegouwen, Mark I., Van Sandick, Johanna W., Cuesta, Miguel A., Van Der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Scheepers, Joris J.G., Sosef, Meindert N., Van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, De Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin Ichi, Chen, Haiquan, Law, Simon Y.K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Hulshof, Maarten C.C.M., Van Laarhoven, Hanneke W.M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G.W., and Gisbertz, Suzanne S.

Published
2019

27. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study

Author

Hagens, Eliza R. C., Henegouwen, Mark I. van Berge, van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Rasanen, Jari, Nafteux, Philippe, Pattyn, Piet, Hoelscher, Arnulf H., Schroeder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Roig Garcia, Josep, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flavio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., Gisbertz, Suzanne S., Hagens, Eliza R. C., Henegouwen, Mark I. van Berge, van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Rasanen, Jari, Nafteux, Philippe, Pattyn, Piet, Hoelscher, Arnulf H., Schroeder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Roig Garcia, Josep, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flavio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., and Gisbertz, Suzanne S.

Abstract

BackgroundAn important parameter for survival in patients with esophageal carcinoma is lymph node status. The distribution of lymph node metastases depends on tumor characteristics such as tumor location, histology, invasion depth, and on neoadjuvant treatment. The exact distribution is unknown. Neoadjuvant treatment and surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy has not been reached. The aim of this study is to determine the distribution of lymph node metastases in patients with resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed. This can be the foundation for a uniform worldwide staging system and establishment of the optimal surgical strategy for esophageal cancer patients.MethodsThe TIGER study is an international observational cohort study with 50 participating centers. Patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately individually analyzed by pathological examination. The aim is to include 5000 patients. The primary endpoint is the distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival.DiscussionThe TIGER study will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatmen

Published
2019

28. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining

Author

van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., Meijer, Sybren L., van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., and Meijer, Sybren L.

Published
2018

29. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining

Author

van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., Meijer, Sybren L., van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., and Meijer, Sybren L.

Published
2018

30. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining

Author

van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., Meijer, Sybren L., van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., and Meijer, Sybren L.

Published
2018

31. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining

Author

Pathologie Groep Bovenschen, Pathologie Opleiding, Pathologie Pathologen staf, Cancer, van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., Meijer, Sybren L., Pathologie Groep Bovenschen, Pathologie Opleiding, Pathologie Pathologen staf, Cancer, van der Wel, Myrtle J., Duits, Lucas C., Pouw, Roos E., Seldenrijk, Cornelis A., Offerhaus, G. J.A., Visser, Mike, ten Kate, Fiebo J., Biermann, Katharina, Brosens, Lodewijk A.A., Doukas, Michael, Huysentruyt, Clement, Karrenbeld, Arend, Kats-Ugurlu, Gursah, van der Laan, Jaap S., van Lijnschoten, G. Ineke, Moll, Freek C.P., Ooms, Ariadne H.A.G., van der Valk, Hans, Tijssen, Jan G., Bergman, Jacques J., and Meijer, Sybren L.

Published
2018

32. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer

Author

Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, van Lanschot, J. Jan B, Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, and van Lanschot, J. Jan B

Published
2017

33. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia

Author

Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., Bergman, Jacques J G H M, Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., and Bergman, Jacques J G H M

Published
2017

34. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus

Author

Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, Sharma, Prateek, Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, and Sharma, Prateek

Published
2017

35. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer

Author

Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, van Lanschot, J. Jan B, Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, and van Lanschot, J. Jan B

Published
2017

36. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia

Author

Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., Bergman, Jacques J G H M, Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., and Bergman, Jacques J G H M

Published
2017

37. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus

Author

Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, Sharma, Prateek, Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, and Sharma, Prateek

Published
2017

38. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia

Author

Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., Bergman, Jacques J G H M, Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., and Bergman, Jacques J G H M

Published
2017

39. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus

Author

Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, Sharma, Prateek, Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, and Sharma, Prateek

Published
2017

40. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer

Author

Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, van Lanschot, J. Jan B, Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, and van Lanschot, J. Jan B

Published
2017

41. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer

Author

Pathologie patiënten zorg, Cancer, Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, van Lanschot, J. Jan B, Pathologie patiënten zorg, Cancer, Biermann, Katharina, Shapiro, Joel, van Klaveren, David, Offerhaus, G. Johan A., Ten Kate, Fiebo J.W., Meijer, Sybren L., van Berge Henegouwen, Mark I, Steyerberg, Ewout W., Wijnhoven, Bas P L, and van Lanschot, J. Jan B

Published
2017

42. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus

Author

Pathologie patiënten zorg, Cancer, Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, Sharma, Prateek, Pathologie patiënten zorg, Cancer, Vennalaganti, Prashanth, Kanakadandi, Vijay, Goldblum, John R, Mathur, Sharad C, Patil, Deepa T, Offerhaus, G. Johan, Meijer, Sybren L., Vieth, Michael, Odze, Robert D, Shreyas, Saligram, Parasa, Sravanthi, Gupta, Neil, Repici, Alessandro, Bansal, Ajay, Mohammad, Titi, and Sharma, Prateek

Published
2017

43. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia

Author

Pathologie patiënten zorg, Cancer, Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., Bergman, Jacques J G H M, Pathologie patiënten zorg, Cancer, Duits, Lucas C., van der Wel, Myrtle J., Cotton, Cary C., Phoa, K. Nadine, ten Kate, Fiebo J W, Seldenrijk, Cees A., Offerhaus, G. Johan A, Visser, Mike, Meijer, Sybren L., Mallant-Hent, Rosalie C., Krishnadath, Kausilia K., Pouw, Roos E., Tijssen, Jan G P, Shaheen, Nicholas J., and Bergman, Jacques J G H M

Published
2017

44. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction : A prospective follow-up study

Author

Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, Krishnadath, Kausilia K., Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, and Krishnadath, Kausilia K.

Published
2015

45. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel

Author

Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., Bergman, Jacques J G H M, Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., and Bergman, Jacques J G H M

Published
2015

46. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction : A prospective follow-up study

Author

Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, Krishnadath, Kausilia K., Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, and Krishnadath, Kausilia K.

Published
2015

47. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction : A prospective follow-up study

Author

Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, Krishnadath, Kausilia K., Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, and Krishnadath, Kausilia K.

Published
2015

48. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel

Author

Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., Bergman, Jacques J G H M, Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., and Bergman, Jacques J G H M

Published
2015

49. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: A prospective follow-up study

Author

Pathologie Pathologen staf, Pathologie, Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, Krishnadath, Kausilia K., Pathologie Pathologen staf, Pathologie, Davelaar, Akueni L., Calpe, Silvia, Lau, Liana, Timmer, Margriet R., Visser, Mike, ten Kate, Fiebo J., Parikh, Kaushal B., Meijer, Sybren L., Bergman, Jacques J., Fockens, Paul, and Krishnadath, Kausilia K.

Published
2015

50. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel

Author

Pathologie Pathologen staf, Cancer, Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., Bergman, Jacques J G H M, Pathologie Pathologen staf, Cancer, Duits, Lucas C., Phoa, K. Nadine, Curvers, Wouter L., Ten Kate, Fiebo J W, Meijer, Gerrit A., Seldenrijk, Cees A., Offerhaus, G. Johan, Visser, Mike, Meijer, Sybren L., Krishnadath, Kausilia K., Tijssen, Jan G P, Mallant-Hent, Rosalie C., and Bergman, Jacques J G H M

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results